President's overview of ASCO 2012

Afatinib delays progression of advanced lung adenocarcinomas

Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

Increased progression-free survival in advanced lung cancer with afatinib

Prognostic biomarkers and next generation genomic sequencing

Bringing together the resources of Eastern and Western European institutes

Recent developments in neoadjuvant therapy

Highlights and goals of IMPAKT 2012

PI3K and the heterogeneity of small tumour breast cancer

Molecularly characterising triple negative breast cancer

Overcoming drug resistance and targeting critical pathways